Ondine Biomedical Inc, the Canadian-headquartered life sciences company focused on light-based infection control technologies, has announced that its annual general meeting (AGM) will take place on 30 June 2025. The company, whose shares trade on the London Stock Exchange's AIM market, confirmed the date in a regulatory filing published today.
The AGM will be held virtually, allowing shareholders to participate remotely. Items on the agenda include the receipt of the audited financial statements for the year ended 31 December 2024, the re-election of directors, and the appointment of auditors. The board will also seek approval for the company's remuneration report and any share option plans.
Ondine Biomedical specialises in photodisinfection technologies used to prevent hospital-acquired infections. Its lead product, Steriwave, is a rapid nasal photodisinfection treatment designed to reduce surgical site infections. The company has faced a challenging period on the markets, with its shares trading at around 11p, down significantly from their 2021 highs of over 60p.
For UK investors, the AGM provides an opportunity to hear directly from management about the company's commercial progress, particularly its efforts to secure regulatory approvals and distribution partnerships in Europe and North America. The meeting will also address the company's cash runway and any potential fundraising requirements.
Analysts note that Ondine's financial position remains tight, with the company reporting a net loss of £6.2 million in its most recent full-year results. The AGM will be closely watched for any updates on clinical trial data or new commercial contracts that could affect the share price.
Source: Ondine Biomedical regulatory filing